Kenneth I. MochPresident and CEO at Cognition Therapeutics, Inc.
Kenneth Moch is President & CEO of Cognition Therapeutics, a clinical stage neuroscience company developing Elayta™, a novel small molecule designed to protect and restore synaptic function in individuals suffering from Alzheimer’s disease. Mr. Moch has previously been President & CEO of four life science companies (Chimerix, BioMedical Enterprises, Alteon and Biocyte), a co-founder of The Liposome Company, and a management consultant with McKinsey. He is a member of the Board of the Biotechnology Innovation Organization, where he chairs BIO’s Bioethics Committee and co-chairs the ECS Regulatory Policy Subcommittee, and a member of the Boards of Zynerba Pharmaceuticals and Gamida Cell. He is a founding member of the NYU Working Group on Compassionate Use and Pre-Approval Access. Mr. Moch holds an A.B. in biochemistry with a minor in health policy from Princeton University and an MBA from Stanford University.